This phase I trial is trying to understand how safe, effective and well tolerated a new oral cancer drug is, in combination with chemotherapy, for the treatment of patients with ovarian, peritoneal or fallopian tube cancer.
This trial is treating patients with ovarian, peritoneal or fallopian tube cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Eligible patients will receive oral ZN-c3 once daily in 21-day treatment cycles, in combination with one of two possible intravenous chemotherapy drugs (carboplatin or PLD).
Recruiting Hospitals Read More